• DELIVER (Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection
Fraction) 1 is an industry-funded Phase 3, double-blind, event-driven, randomized …

In 2015, publication of the results of the BI 10773 (empagliflozin) Cardiovascular Outcome
Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) heralded the …

Aims Sodium-glucose co-transporter 2 inhibitor (SGLT2i), initially introduced for the
treatment of diabetes mellitus (DM), demonstrates cardiovascular and renal benefits in …

An old story describes a farmer who led a contented life until he found out about the
existence of precious stones. He became so fascinated with diamonds, that he traveled …

Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a class of oral
antiglycemic agents that have emerged as a new therapeutic strategy for heart failure (HF) …

Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve blood glucose control by
blocking renal glucose reabsorption with little subsequent risk of hypoglycemia …

Primarily, a comprehensive view of the cost considerations for prescribing SGLT-2i has been
excluded, as accessibility and affordability of these medications in deprived regions …

Large clinical trials involving type 2 diabetes (T2D) patients have shown that sodium-
glucose transporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure …

Background: Heart failure (HF) prognosis without therapy is poor, however introduction of a
range of drugs has improved it. We aimed to perform a protocol for systematic review and …